Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-Month Open-label Extension Study of SEP-4199 CR in Bipolar I Depression
jRCT2031220302Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Open-label trial of SEP-4199 in bipolar I disorder (2 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Safety (adverse events). Started Mar 2022; status: completed.
02
Drugs
SEP-4199
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on jRCT2031220302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220302.